This company listing is no longer active
CTIC Stock Overview
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
CTI BioPharma Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.09 |
| 52 Week High | US$9.10 |
| 52 Week Low | US$4.01 |
| Beta | 0.83 |
| 1 Month Change | 0.44% |
| 3 Month Change | 112.38% |
| 1 Year Change | 66.18% |
| 3 Year Change | 690.43% |
| 5 Year Change | 73.47% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch
Aug 17CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M
Aug 08CTI BioPharma: Approval Is Great, Now There's The Follow Through
Jul 19CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis
Jul 07CTI BioPharma - 3.2x Potential Upside On A De-Risked Asset
May 04CTI BioPharma Corp.: Pacritinib Approval, Downgrade To A Sell Rating
Apr 11CTI BioPharma: A Speculative Buy Into The PDUFA Date
Mar 01CTI BioPharma: Long And Troubled History, Finally Approaching Approval
Dec 24FDA grants 'priority review' status to CTI Biopharma's pacritinib NDA
Jun 01CTI BioPharma initiated buy at Stifel; cites potential in myelofibrosis
May 06CTI BioPharma: Accelerated Approval Pathway Looks Attractive
Dec 06Shareholder Returns
| CTIC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.1% | 0.2% | -0.2% |
| 1Y | 66.2% | -4.7% | 25.6% |
Return vs Industry: CTIC exceeded the US Biotechs industry which returned 7.4% over the past year.
Return vs Market: CTIC exceeded the US Market which returned 12% over the past year.
Price Volatility
| CTIC volatility | |
|---|---|
| CTIC Average Weekly Movement | 25.3% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 18.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CTIC's share price has been volatile over the past 3 months.
Volatility Over Time: CTIC's weekly volatility has increased from 15% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 128 | Adam Craig | www.ctibiopharma.com |
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.
CTI BioPharma Corp. Fundamentals Summary
| CTIC fundamental statistics | |
|---|---|
| Market cap | US$1.20b |
| Earnings (TTM) | -US$69.24m |
| Revenue (TTM) | US$75.77m |
15.8x
P/S Ratio-17.3x
P/E RatioIs CTIC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTIC income statement (TTM) | |
|---|---|
| Revenue | US$75.77m |
| Cost of Revenue | US$4.46m |
| Gross Profit | US$71.31m |
| Other Expenses | US$140.55m |
| Earnings | -US$69.24m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.53 |
| Gross Margin | 94.11% |
| Net Profit Margin | -91.38% |
| Debt/Equity Ratio | -459.4% |
How did CTIC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/28 11:11 |
| End of Day Share Price | 2023/06/23 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CTI BioPharma Corp. is covered by 18 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Fabrizio Spagna | Axia Financial Research |
| Leah Rush Cann | Brookline Capital Markets |
| null null | BTIG |